Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 9Recruiting 7Unknown 4Active not recruiting 4Terminated 3Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Prostatic Neoplasms 56Breast Neoplasms 49Lung Neoplasms 31Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 14Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Adenocarcinoma of Lung 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Triple Negative Breast Neoplasms 3Advanced Non-Small Cell Lung Cancer 3Adenocarcinoma, Bronchiolo-Alveolar 3Solid Tumor 2Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Inflammatory Breast Neoplasms 2Hormone Refractory Prostate Cancer 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × Docetaxel × Clear all
NCT04095689 2026-01-23

INTEGRAL

The Methodist Hospital Research Institute

Phase 2 Terminated
8 enrolled 10 charts
Breast

Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02124902 2022-11-07

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

Washington University School of Medicine

Phase 2 Terminated
148 enrolled 9 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡